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1. Introduction 
The heritability of cancers is usually affected by complex interactions between carcinogens 
and the host's genome. New aspects of the genetics of cancer pathogenesis, such as DNA 
methylation, and micro RNAs are increasingly recognized as important events. 
Chemotherapeutic drugs interfere with cell division in different ways, e.g. with the 
duplication of DNA or the separation of newly formed chromosomes. Most forms of 
chemotherapy target rapidly dividing cells and are not specific for cancer cells, although 
some degree of specificity may come from the inability of many cancer cells to repair DNA 
damage. Hence, chemotherapy has the potential to harm healthy tissues, especially those 
tissues that have a high replacement rate (e.g. intestinal lining). These cells usually repair 
themselves after chemotherapy.[1] DNA has long been considered a favored target for cancer 
chemotherapeutic agents. Indeed many of the most effective clinical agents, such as 
alkylating and interactive agents, are DNA interactive. Achieving the desired sequence 
specificity with DNA-interactive agents is considered to be one of the most formidable 
hurdles in the development of new agents to achieve therapeutic invention.[2] 
Certain structural features of the alpha helix are particularly important when considering 
drug-DNA interaction. Double helical DNA is not a uniform structure, there are places where 
the strands are further apart, and where they are closer together, these are known as major and 
minor grooves. In B-DNA, the major groove is wider (12 versus 6 Å) and deeper (8.5 versus 7.5 
Å) than the minor groove, making it more accessible to interacting molecules. The base pair 
arrangement for each groove is very specific, each containing certain hydrogen bond donors 
and acceptors. In addition, the major groove will also contain the methyl group of thymine 
and drug molecules or proteins bind at these sites. More importantly the difference between 
the donor and acceptor groups in each groove, this makes it possible for drug molecules to 
selectively distinguish between the different bases as well as sequences of bases.[3,4] 
2. DNA groove binders 
Drugs that bind to DNA may occur on the major groove face, minor groove face or a 
combination. The grooves are excellent sites for sequence specific recognition since there are 
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many potential hydrogen bond donor and acceptor atoms unique to each base pair 
combination along the base edges. The greater width associated with the B-DNA major 
groove makes the major groove a somewhat more preferable binding groove. Groove 
binding can be via the major or minor groove and covalently or non-covalently. Most DNA 
interactive proteins bind in the major groove, while small molecules of less than 1000 Da, 
including many antibiotics, bind in the minor groove.  
 
Fig. 1. Hydrogen bonding betweeb adenosine/thymine (left) and guanosine/cytosine base 
pairs of DNA. 
The minor groove represents a vulnerable site of attack in that it is normally unoccupied, 
and this is presumably the reason for the evolution of antibiotics that attack the DNA of 
competing organisms. Thus, although at first sight minor groove binders are less attractive 
as probes in that they target the less information rich minor groove nevertheless, they may 
prove to have several advantages compared with major groove ligands. The development of 
sequence-specific probes based on naturally occurring DNA groove-binding agents is, 
therefore, an alternative and complementary approach to the antisense oligonucleotide 
strategy. The main motive for synthesizing a large number of analogues and conjugates of 
naturally occurring minor groove-binding agents, is to generate new lead compounds with 
potential anticancer properties and specific DNA sequence recognition.[5] 
2.1 Covalent binding in the minor groove of DNA 
Drugs which bind covalently to DNA are used to either add substituents onto base residues, 
or to form cross-links between different sections of DNA. The first mechanism results in a 
base-pairing mismatch during DNA replication, and the DNA is ultimately fragmented by 
the enzymes which try to repair it. The second mechanism binds together the two strands of 
DNA helix, preventing separation during the replication process. Electrophilic functional 
groups such as epoxides, aziridines, carbinolamines, imines and cyclopropanes are found in 
a variety of synthetic and natural products capable of covalent interaction with DNA; 
examples include mitomycin, saframycins and pyrrolobenzodiazepines (anthramycin).[6] 
Non-covalent binding compounds are typically isohelical with B-DNA and fits snugly 
within the minor groove, held in a position by a combination of hydrogen bonds, van der 
Waal forces and electrostatic interactions; examples include distamycin,[7] netropsin,[8] 
lexitropsins and bis-benzimidazole (Hoecht 33258).[9] 
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2.2 Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) as DNA binding agents 
Binding of low molecular weight ligands to DNA causes a wide variety of potential 
biological responses. In this context pyrrolo[2,1-c][1,4]benzodiazepines (PBDs), a group of 
potent naturally occurring antitumour antibiotics isolated from various Streptomyces species, 
are one of the promising type of lead compounds. They differ in the number, type and 
position of substituent in both their aromatic A-ring and pyrrolidine C-ring, and in the 
degree of saturation of the C-ring which can be either fully saturated or unsaturated at 
either the C2-C3 (endocyclic) or C2 (exocyclic) positions. There is either an imine or 
carbinolamine methylether moiety at the N10-C11. Position, which is an elecrophilic centre 
responsible for alkylating DNA. To date, thirteen structures isolated, include compounds 
like anthramycin,[6] mazethramycin,[10] porothramycin,[11] prothracarcin,[12] sibanomycin,[13] 
tomaymycin,[14] sibiromycin,[15] chicamycin A,[16] neothramycin A, B[17] and DC-81[18]  
(Figure 2). 
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Fig. 2. Naturally occurring PBDs. 
The PBD interactions with DNA are unique since they bind within the minor groove of 
DNA forming a covalent aminal bond between the C11-position of the central B-ring and the 
N2 amino group of a guanine base.[19] The cytotoxic and antitumour activity of PBDs are 
attributed to their ability to form covalent DNA adducts. Molecular modeling, solution 
NMR, fluorimetry and DNA foot printing experiments have shown that these molecules 
have a preferred selectivity for Pu-G-Pu sequences[14,20] that are oriented with their A-rings 
pointed either towards the 3' or 5' end of the covalently bonded DNA strand (as in case of 
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anthramycin and tomaymycin). The PBDs have been shown to interfere with the action of 
endonuclease enzymes on DNA[21] and to block transcription by inhibiting DNA polymerase 
in a sequence specific manner,[22] processes which may be relevant for the biological activity. 
The known PBD natural products have a (S) configuration at the C11a-position, which 
provides them with a right-handed twist when viewed from the C-ring towards the A-ring. 
This has given the appropriate three-dimensional shape for isohelicity with the minor 
groove of DNA, leading to a snug fit at the binding site. Recemization at C11a can 
significantly reduce both DNA binding affinity and in vitro cytotoxicity. A synthetic PBD 
with the (R)-configuration at C11a was shown to be devoid of both DNA binding affinity 
and in vitro cytotoxicity.[23] The N10-C11 imine moiety may exist in the hydrated form 
depending upon precise structure of the compound and the method of isolation or synthetic 
workup. Imines and methyl ether forms are interconvertable by dissolution of imine in 
methanol or by several cycles of refluxing the methyl ether in chloroform followed by 
evaporation of the solvent in vacuum (Figure 3). 
 
 
 
 
 
Fig. 3. Carbinolamine-methylether-imine interconversions in the PBDs. 
The mechanism of action of the PBDs is associated with their ability to form, an adduct in 
the minor groove, thus interfering with DNA processing. After insertion in the minor 
groove, an aminal bond is formed through nucleophilic attack of the N2 of a guanine base at 
the electrophillic C11 position of PBD. X-Ray diffraction studies on crystals of anthramycin 
methylethers have shown that the molecule is twisted 0-50° from one end to the other along 
the axis, and this might fit into one of the grooves of DNA. In the CPK models, the drug fits 
snugly within the narrow groove without distortion of the DNA helix. The structure of the 
anthramycin DNA adduct was initially studied independently by Hurley and Kohn using 
indirect techniques,[24] but more recently fluorescence spectroscopy, high field NMR and 
molecular modeling have been employed (Figure 4). 
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Fig. 4. Proposed mechanism for formation of the anthramycin deoxyguanosine adduct in 
DNA, showing formation of an aminal bond betweeb the C11 position of the PBD and 
exocyclic N2 of guanine base. 
2.3 Preparation of PBDs 
Biosynthesis of the naturally occurring PBDs have been extensively elucidated by Hurley 
and co-workers. The first total synthesis of a carbinolamine containing PBD of anthramycin 
has been reported by Leimgruber in 1968.[25] Extensive reviews of the synthetic literature of 
the PBDs have appeared in 1994, 1998 and 2002.[26] Various approaches to the synthesis of 
PBD antibiotics have been investigated, including hydride reduction of seven-membered 
cyclic dilactams,[27] reductive cyclization of acyclic nitroaldehydes,[28] iminothioether 
approach[29] cyclization of aminothioacetals,[30] deprotective cyclization of the 
diethylthioacetals via N10 protected precursors,[31] oxidation of cyclic secondary amines,[32] 
reductive cyclizations[33] and solid phase approaches.[34] Various synthetic methods for the 
synthesis of the PBDs have been reviewed extensively. The N10-C11 carbinolamine, or its 
chemical equivalent, is a prerequisite for antitumour activity. Several research groups have 
designed new PBDs with potential DNA binding affinity.[35-39] 
A novel method for the oxidation of PBD secondary amine to the corresponding imines is 
developed in this laboratory32. Although PBDs with either a secondary amine or amide 
functionality at N10-C11 are readily synthesized, the introduction of imine or carbinolamine 
at this position is problematic due to the reactivity of these functional groups. As described 
in the literature, the cyclic secondary amine precursors have been readily prepared from 
corresponding nitroaldehydes. This upon oxidation with DMSO/(COCl)2 or TPAP (tetra-n-
propyl ammonium perruthenate) gives the corresponding imines in good yields (Scheme 1). 
The same group has carried out another interesting study on the enzymatic reduction of aryl 
azides to aryl amines by employing baker's yeast. This biocatalytic reductive methodology 
has been applied to the chemoenzymatic synthesis of PBDs via the reductive cyclization of 
arylazido aldehydes.[33,40] 
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Scheme 1. Reagents and conditions: (i) Pd/C; (ii) Raney Ni; (iii) swern/TPAP. 
3. Structure activity relationship studies 
The naturally occurring PBDs namely anthramycin, tomaymycin, sibiromycin, neothramycin 
and DC-81 have different type of substitutions. The electron-donating substituents are 
required in the aromatic A ring for biological activity. Bulky substituent like a sugar moiety at 
C7 position enhances the DNA binding affinity and cytotoxicity. It is interesting to note that C 
ring modified PBDs appear to provide both greater differential thermal stabilization of DNA 
duplex and significantly enhance kinetic reactivity during covalent adduct formation. 
Similarly, the C2-substituted naturally occurring PBDs exhibit more cytotoxicity compared to 
their unsubstituted counter parts as shown in Figure 5. Based on these considerations a 
structure activity relationship has been derived by Thurston and co-workers. 
N
N
H
R9
R8
R7
O
R
1
2
3
10
11
11a
(a) An imine, carbinolamine
methyl ether required at N10-C11
(b) (S)-Stereochemistry
required at C11a
(c) Replacement of C1 with
an oxygen maintains
cytotoxicity
(d) Endocyclic or exocyclic
unsaturation at C2 enhances
cytotoxicity and in vivo
antitumour activity. Fully
unsaturated C-ring leads to
complete loss of DNA-binding
and cytotoxicity
(e) Small substituents (eg. -OH)
tolerated at C3 in fully saturated
C-ring compounds
(f) Sugar moiety at C7
enhances DNA-binding
affinity and cytotoxicity
in some cell lines
(g) Electron-donating
substituents required
at position 7,8 or 9
of A-ring
(h) Bulky substituents at N10
(eg. acetyl) inhibit DNA-
binding and cytotoxicity
A
B
C
 
Fig. 5. Structure activity relationship of PBD ring system. 
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3.1 PBD A-ring modifications 
Baraldi and co-workers[41] have investigated heterocyclic analogues of pyrrolo-[2,1-
c][1,4]benzodiazepine (PBD) by replacing A ring with pyrazolo[4,3-e]-pyrrolo[1,2-
c][1,4]diazepinone ring system. Some of these ring pyrazole PBD analogues exhibited 
interesting profile of cytotoxicity. Similarly, Thurston and co-workers[42] have synthesized 
some other A-ring heterocyclic PBDs and evaluated their DNA binding affinity. In this 
study pyrazine and pyrimidine A-ring analogues of PBDs have been prepared and 
evaluated for their cytotoxic potential. It is observed that the aromatic A-ring has a modest 
influence on thermal denaturation of DNA. They have also synthesized some tetracyclic 
PBD analogues like dioxolo[4,5-h]-pyrrolo[2,1-c]benzodiazepine-5-one and dieoxano[2,3-
h]pyrrolo[2,1-c]benzodiazepine-5-one and they have observed that the addition of dioxazole 
or dioxazine rings to existing A ring of DC-81 significantly reduces DNA binding affinity 
(Tm = 0.1 to 0.5 ºC) and cytotoxicity [IC50 = 0.26-3.4 M] compared to DC-81. 
 
3.2 B-ring modifications 
There are reports on B-ring modifications and one of them describes the synthesis and 
antitumour activity of pyrrolo[2,1-c][1,4]benzodiazepine derivatives and these compounds 
exhibit moderate antitumour activity. To investigate the role played by the non-covalent 
interactions Robba and co-workers[43] have synthesized a series of PBDs having N10-C11 
amidine functionality and evaluated the DNA binding through thermal denaturation 
studies. It is observed that some of these compounds cause a significant increase in melting 
of calf thymus DNA comparable to the naturally occurring DC-81. 
 
3.3 C-ring modifications 
A number of naturally occurring PBDs namely anthramycin, tomaymycin, sibiromycin and 
neothramycin have different type of substitutions in the C ring. It is interesting to note that 
these C ring modified PBDs appear to provide both greater differential thermal stabilization 
of DNA duplex and significantly enhance kinetic reactivity during covalent adduct 
formation. Similarly, the C2 subistituted naturally occurring PBDs exhibit more cytotoxicity 
compared to their unsubstituted counter parts. Thurston and co-workers[44] have 
synthesized a series of C2-exo unsaturated PBDs, and C2-C3-endo unsaturated PBDs C-ring 
enhances both DNA-binding reactivity and in vitro cytotoxic potency. Recently the same 
group has reported the synthesis of novel C2-aryl 1,2/2,3-endo unsaturated 
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pyrrolobenzodiazepines as potential antitumour agents and synthesized novel C2-C3 
unsaturated PBD analogues containing conjugated acrylyl C2 substituents, these analogues 
possess not only significant cytotoxicity (in the NCI 60-cell line screen with surprisingly 
potency equivalent to anthramycin) but als better DNA binding ability.[45] 
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Recently, a series of C2-fluorinated PBDs[46] have synthesized and they have been screened 
for in vitro cytotoxicity against a number of cancer cell lines. The C2-fluorinated PBDs 
significantly increase the thermal stability of the calf thymus DNA duplex and also these 
compounds shows 550 fold increase in activity against the CH1 cell line when compared to 
the unsubstituted PBDs. A ring substituted C2-fluorinated monomers of PBD and DC-81 
dimers have also been synthesized in this laboratory.[47] These compounds have shown 
good DNA binding ability when compared to A-ring unsubstituted C2-fluorine compounds. 
Moreover, such fluorinated compounds possess in vitro anticancer activity in a number of 
human cancer cell lines (Figure 6). 
 
 
Fig. 6. Structure of fluorinated PBD monomer derivatives shown in a significant increase in 
melting for calf thymus dna comparable to the naturally occuring DC-81 
3.4 PBD conjugates 
The research of antineoplastic agents is based on the fact that a single molecule of PBD 
exhibits higher DNA binding affinity as well as more anticancer activity, if it contains more 
than one pharmacophore, each with different mode of action and capable of recognizing 
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heterogeneous DNA sequences. For this reason, several research groups developed new 
PBD conjugates, such as cyclopropylbenzindole, distamycin, and netropsin. Synthesis of 
PBD conjugates has been carried out employing mainly pyrrolobenzodiazepine DC-81, that 
is linked mostly at C8 position to different moieties; rare examples of C2 linkage were 
described in literature these last years.48 
The PBDs have also been used as a scaffold to attach ethylenediamine tetraacetic acid 
(EDTA),[49] epoxide,[50] polyamide[51] and oligopyrrole moieties[52] leading to novel hybrids of 
PBD, which have exhibited sequence selective DNA-cleaving and cross-linking properties. 
EDTA moiety has been linked to the PBD skeleton (DC-81) to study the covalent binding to 
DNA and its sequence selectivity.[53] Detailed analysis of the cleavage sites by laser 
densitometry suggested that the results are best explained by two major modes of 
binding/cleaving for (EDTA/DC-81)FeII. The EDTA-PBD conjugate covalently binds to 
DNA at 5′-PuGPu sequences leading to site specific cleavage. 
Confalone and co-workers[54] have synthesized a PBD analogue with an epoxide group 
substituted at C11a position with the objective of producing a PBD monomer with DNA 
cross-linking ability, whereas no DNA binding data has been reported. Since attachment at 
C11a position could sterically hinder the DNA binding, interstrand guanine-guanine cross-
linking C8 epoxide containing PBD has been designed and synthesized. It has been 
considered that the attachment of the epoxide through the C8 position could retain the 
isohelicity with the contour of the minor groove of the host DNA molecule.[55] 
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Baraldi and co-workers[56] have designed and synthesized distamycin-PBD and netropsin-
PBD conjugates as novel sequence selective C8-linked PBD hybrids. These hybrids 
containing 1 to 4 pyrrole units have been investigated for the sequence selectivity and 
stability of DNA drug complexes. 
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Lown and co-workers[57] have also reported the synthesis of a series of PBD-lexitropsin 
conjugates linked through the C8 position with a suitable linker. The conjugation has been 
achieved by amidic linkage to amine of the lexitropsin unit with the acid moiety of the 
linker attached to the PBD system. These compounds have been synthesized in view of the 
effect of their sequence selective binding in DNA duplex. 
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Hurley and co-workers[58] have synthesized novel DNA-DNA interstrand adenine-guanine 
cross-linking UTA-6026 compound. Preliminary in vitro tests showed that UTA-6026 has 
remarkable potent cytotoxicity to several tumour cell lines (IC50 = 0.28 nM in human breast 
tumour cell line MCF-7, IC50 = 0.047 nM in colon tumour cell line SW-480 and IC50 = 5.1 nM 
in human lung tumour cell line A549). 
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Denny and co-workers[59] have designed and synthesized unsymmetrical DNA cross-linkers 
by linking the seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indo-4-one (seco-CBI) to PBD 
moiety. These compounds have anticipated cross-linking between N3 of adenine and N2 of 
guanine in the minor groove of DNA. 
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Recently, Wang and co-workers[60] have synthesized indole and enediyne PBD conjugates as 
potential antitumor agents and explained the correlation between antitumor activity and 
apoptosis. 
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In the past few years, this research group prepared different type of conjugates, in which a 
known antitumor compound or some simple active moiety tethered to PBD have been 
designed, synthesized and evaluated for their biological activity (Figure 7).[61-73] A series of 
PBD conjugates by linking different DNA interacting ligands such as benzimidazoles, 
benzothiazoles, naphthalimides, aryl substituted naphalens, chalcones and poly-aromatic 
hydrocarbons (pyrene amine, chrysene amine and phenanthrinephenyl) by using varying 
linker length to enhance the DNA binding affinity and antitumour activity. PBD-
morpholine, N-methyl piperizine and N,N-dimethyl amine hybrids have been prepared in 
an attempt to improve the water solubility and cytotoxicity of the PBD compounds. 
N
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oC  
The DNA binding ability of these novel PBD conjugates is usually investigated by thermal 
denaturation studies using calf thymus (CT) duplex DNA at pH 7.0 employing the protocols 
reported in the previous studies.[67,74] All the PBD conjugates showed better melting 
temperature of CT-DNA compared to the naturally occurring DC-81. The DNA melting 
temperature studies indicate that these PBD conjugates exhibit significant DNA binding 
affinity. The PBD conjugates are effective as DNA binding agents particularly at G-rich 
sequences.[75] Additionally when the restriction enzyme digestion assay (RED assay) was 
carried out for some representative compounds along with the DC-81.  This study clearly 
indicated that most of the conjugates effectively bind at G-rich region of the minor groove of 
DNA even at lower concentrations. These studies clearly indicate that the linking of the PBD 
scaffold with other conjugate partners not only enhances the binding potential significantly 
but also increases the base pair sequence selectivity. With regard to the PBD scaffold it is 
well established that it forms a covalent linkage at the N2 position of a guanine base of the 
DNA while the other subunit of this new conjugate is likely to interact within the DNA 
through the non-covalent interactions.[63,76] This aspect has been investigated in detail in case 
PBD–naphthalimide and benzimidazole conjugates examine their sequence selective 
binding ability. 
 
All the PBD–naphthalimide conjugates also showed promising anticancer activity with GI50 
values of less than 0.1 to 0.5 M against human cancer cell lines. One of the conjugate 
exhibited significant DNA binding affinity, that is the ∆Tm is 25.9 at      0 C. The DNA 
binding of this conjugate to d(AACAATTGTT)2 was studied by a combination of high-
resolution 1H and 31P 2D NMR spectroscopy and restrained molecular dynamic calculations  
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Fig. 7. Some representative PBD conjugates. 
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in explicit solvent. The bifunctional hybrid binds with its PBD moiety covalently linked 
within the minor groove to a guanine with an S stereochemistry at its covalent linkage site at 
C11 and a 5’-orientation of its A-ring carrying the linker with the naphthalimide ligand. The 
latter inserts from the minor groove between an A–A. T–T base pair step resulting in an 
opposite buckling of the base pairs at the intercalation site and duplex unwinding at 
adjacent internucleotide steps. There is NMR spectroscopic evidence that the naphthalimide 
undergoes a ring-flip motion with exchange rates slow to intermediate on the chemical shift 
time scale at ambient temperatures (Figure 8).[77] 
PBD-benzimidazole conjugates also binds in the DNA minor groove with a preference for 
(A,T)4G sequences. Whereas the binding of both ligands is enthalpy-driven and associated 
with a negative entropy, the benzimidazole hybrid exhibits a less favourable binding 
enthalpy that is counterbalanced by a more favourable entropic term when compared to the 
naphthalimide hybrid.[78] 
 
a b c 
Fig. 8. a. Final energy-minimized structure of the PBD-naphthalimide-(AACAATTGTT)2 
complex; view into the minor groove illustrating the position and orientation of the drug (in 
yellow) and the naphthalimide intercalation site. b. Close up viwe into the minor groove of 
the PBD-naphthalimide-(AACAATTGTT)2 complex residues G8 and T9 as well as A14 and 
A15 positioned on the H11a and H11 side of the covalently bound (11s, 11aS) PBD moiety 
are highlighted. c. Top view of the intercalation site with the naphthalimide, adenine and 
thymine bases colored in orange, yellow and white, repectively; base pair A5 T16 shown on 
top. 
4. PBD dimers and trimers 
A very original and interesting development for the PBD alkylating agents was obtained 
upon synthesis of bifunctional compounds. Suggs and co-workers have linked the two PBD 
moieties through the A-ring at C7/A-C7’ positions by alkanediyldioxy linker (1) and 
investigated the DNA binding properties. These molecules have been rationally designed as 
DNA cross-linkers and they bind reversibly to DNA and protect DNA against the action of 
certain restriction enzymes.[79,80] Lown and co-workers have designed and synthesized PBD 
dimers, joined tail to tail (C-ring) at C2 position through alkylamido linker unit (2). A series 
of these dimers have been evaluated for their cytotoxicity against 9 panels containing 60 
human cell lines. It is observed that these compounds exhibited moderate to promising 
cytotoxic potency against different cancer cells,[81] some of the dimers are shown in Figure 9. 
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Thurston and co-workers have synthesized homologous series of C8 diether-linked PBD 
dimers (3, DSB-120) that span approximately six base pairs of DNA and in which sequence 
selectivity also increased (e.g., purine-GATC-pyrimidine).[82,83] DSB-120 exhibits potent in 
vitro cytotoxicity and enhances DNA binding affinity and sequence specificity as compared 
to the natural occuring DC-81. This improvement in biological activity has been attributed to 
the ability of these compounds to link to DNA irreversibly via guanine residues on opposite 
strands because of the presence of two active sites (i.e., two imine functionalities).[84] The in 
vivo studies of this compound were not encouraging, and the low therapeutic index 
observed was partly due to the reaction of this compound with cellular thiol-containing 
molecules before reacting at the tumor site.[85] Recently, another new cross-linking PBD 
dimer (4, SJG-136) having C2/C2‘-exo unsaturation (that exhibits high DNA binding 
affinity) has been prepared by the same group.[86] This investigation has highlighted the 
effect of C2 unsaturation on the in vitro and in vivo cytotoxic activity. Interestingly, the 
comparison of this PBD dimer with its tetralactam analogue demonstrates that for 
maximum cytotoxicity an electrophilic imine or carbinolamine moiety is essential at the 
N10−C11 position of the PBD units. 
 
Fig. 9. Some of the PBD dimers. 
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SJG-136 (4) is a sequence-selective DNA-interactive agent that is about to enter phase II 
clinical trials for the treatment of malignant disease. Previous studies on the pyrrolo[2,1-
c][1,4]benzodiazepine (PBD) dimers, typified by SJG-136 and DSB-120 (3), have shown that 
these planar ligands react with the exocyclic NH2 groups of two guanine bases in the base of 
the minor groove of DNA to form an irreversible interstrand cross-linked sequence-specific 
adduct. Using high-field NMR, we have characterized and modeled the previously 
predicted interstrand duplex adduct formed by SJG-136 with the self-complementary 5′-
d(CICGATCICG)2 duplex (4). This SJG-136 NMR-refined adduct structure has been 
compared with previous high-field NMR studies of the adducts of the closely related PBD 
dimer DSB-120 with the same duplex and of the adduct of tomaymycin formed with 5′-
d(ATGCAT)2. Surprisingly, the SJG-136 duplex adduct appears to be more closely related to 
the tomaymycin adduct than to that of DSB-120 adduct with respect to the orientation and 
depth of insertion of the ligand within the minor groove. The intrastrand duplex adduct 
formed in the reaction of SJG-136 with the noncomplementary 5′-
d(CTCATCAC)·(GTGATGAG) duplex (4) has also been synthesized and modeled. In this 
duplex adduct, the nature of the cross-link was confirmed, the central guanines were 
identified as the sites of alkylation, and the stereochemical configuration at C11 at both ends 
of the SJG-136 molecule was determined to be S. The NMR-refined solution structures 
produced for the intrastrand adduct confirm the previously proposed structure (which was 
based solely on mass spectroscopy). Both the inter and intrastrand SJG-136 duplex adducts 
form with minimal distortion of the DNA duplex (Figure 10). These observations have an 
impact on the proposal for the mechanism of action of SJG-136 both in vitro and in vivo, on 
the repair of its adducts and mechanism of resistance in cells, and, potentially, on the type of 
pharmacodynamic assay to be used in clinical trials.[89-93] 
 
Fig. 10. Stereoview of the 5′-d(CICGATCICG)2–SJG-136 intrastrand adduct. DNA strands are 
colored blue, and SJG-136(4) is shown in atom colors. Watson–Crick base pairing has been 
maintained, and there is minimal distortion to the β-helical structure of the DNA backbone. 
Models were produced in the SYBYL modeling suite and images produced using UCSF 
Chimera.[94] 
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4.1 Noncross-linking PBD dimers 
This laboratory has been involved in the structural modifications of the PBD ring system and 
development of new synthetic strategies. It is been observed in the literature that no effort has 
been made to prepare and investigate PBD dimers with one imine functionality alone for 
exploring their cytotoxicity as noncross-linking agents (5a-d and 6a,b). These type of PBD 
dimers were prepared to understand the contributions from the non-covalent interactions by 
one of the subunit in such dimers. It was observed that by incorporation of a non-covalent 
component surprising the DNA-binding affinity significantly enhances in such mixed type of 
PBD dimers.[47] One of these dimer with five alkane spacer (5c) elevates the helix melting 
temparature of CT-DNA remarkably to 17.0 ºC after incubation for 18 h at 37 ºC. 
The binding affinity of the compounds was also measured by restriction endonuclease 
digestion assay based on inhibition of the restriction endonuclease BamHI. This study 
reveals the significance of noncovalent interactions in combination with covalent bonding 
aspects when two moieties of structural similarities are joined together. This allows the 
mixed imine-amide PBD dimer with a five carbon chain linker to achieve an isohelical fit 
within the DNA minor groove taking into account both the covalent bonding and the 
noncovalent binding components. This has been supported by binding studies (Figure 11), 
which indicate that the PBD dimer with a five carbon chain linker (5c) gives rise to 
maximum stabilization of the complex with DNA at the minor groove as compared to the 
other PBD dimers with three (5a), four (5b) and eight (5d) carbon chain linkers. The energy 
of interaction for all of the complexes studied was in correlation with the ΔTm values. Mixed 
imine–amine pyrrolobenzodiazepine (PBD) dimers that are comprise of a DC-81 and 
secondary amine (N10) of DC-81 subunits tethered to their C8 positions through 
alkanedioxy linkers (comprised of three and five carbons) was also studied. These noncross-
linking unsymmetrical PBD dimers exhibit significant DNA minor groove binding ability 
and one of them that was 6b linked through the pentanedioxy chain exhibits efficient DNA 
binding ability (ΔTm = 11.0 °C) in compared to naturally occurring DC-81, (ΔTm = 0.7 °C). 
4.2 PBD trimers 
The unsymmetricalbis-1,2,3-triazolo-PBD trimers have been designed and synthesized by 
employing ‘click’ chemistry process. Interestingly, by using this ‘click’ chemistry protocol 
the solubility aspects have been improved that facilitated the purification and isolation of 
the target compounds. These new PBD trimers have shown significant DNA-binding ability. 
Molecular modelling studies substantiate the formation of three covalent bonds with the 
PBD trimer and guanine. One of the representative compound 3c appears to be the optimal 
binder as further increase in linker or chain length decreases the binding strength of these 
compounds with DNA (Figure 12).[95] 
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Fig. 11. Projection diagram showing the DNA-5c and 5b complexs. (a) Side on view and (b) 
down the helix axis. 
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Fig. 12. Covalent bonding of PBD trimer 3c with DNA (guanine residues involved in the 
bonding are written in red color, C-atom of PBD and N-atom of guanine are shown in CPK). 
5. Concluding remarks 
In conclusion, synthesis of imine containing pyrrolobenzodiazepines (PBDs) has often posed 
practical problems towards its isolation and preparation. Based on the biological importance 
of these pyrrolobenzodiazepines (PBDs) enhance the selectivity as well as anticancer 
activity. The design of hybrid ligands has provided a basis for modulating the sequence-
selective binding behavior and/or tailoring the hybrid ligands for mixed-sequence 
recognition. This has also allowed to demonstrate that the design of such hybrids enhances 
anticancer activity as well as stability of drug-DNA complexes. Further some of these 
compounds exhibiting apoptosis inducing ability. Some of the new compounds, PBD-
benzimidazole hybrids and piperazine-linked PBD dimers are undergoing preclinical 
studies. SJG-136 is currently undergoing Phase II evaluation in both the United States 
(through the NCI) and United Kingdom (through Cancer Research United Kingdom). The 
design of mixed dimers has allowed to illustrate the important role played by the non-
covalent interactions in the enhancement of DNA-binding affinity. Interestingly, new PBD 
trimers have shown significant DNA-binding ability, binding and molecular docking 
studies substantiate the formation of three covalent bonds with the PBD trimer and guanine. 
Todate, a large number of PBD best molecules have been synthesized, highlighting that this 
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area of research is extremely important for achieveing considerable importance in the 
recognition of DNA sequences. 
However, this serch for new molecules with enhanced selectivity is in progress inorder to 
recognise about 15 bp for DNA sequences within the human genome. 
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